Kanishk Kumar on 2034 Forecasts for aHUS Associated Thrombotic Microangiopathy
Kanishk Kumar, Digital Marketing Executive at DelveInsight Business Research LLP, shared on LinkedIn:
”Atypical Hemolytic Uremic Syndrome Market 2034: Targeting Complement-Mediated Thrombotic Microangiopathy
Atypical Hemolytic Uremic Syndrome (aHUS), a rare thrombotic microangiopathy caused by uncontrolled complement activation, is advancing with novel C5 inhibitors and factor B blockers in 2034.
Delve Insight‘s report covers epidemiology in the 7MM (US, EU4, UK, Japan), market dynamics, and forecasts, projecting significant CAGR from 2020-2034, with ~4,800 diagnosed cases in 7MM in 2023, ~3,500 in US, and adolescents/adults representing ~80% of cases.
Key Developments in aHUS Market:
December 11, 2025: Novartis launched a Phase 3 study of iptacopan in treatment-naive aHUS patients.
December 8, 2025: Alexion Pharmaceuticals, Inc. disclosed a Phase 3b study of eculizumab in Chinese aHUS patients.
Leading Atypical Hemolytic Uremic Syndrome Companies include Novartis, Hoffmann-La Roche, Chugai Pharmaceutical Co., Ltd., Alexion Pharmaceuticals, Inc. , and others.
Promising therapies include Eculizumab, Crovalimab, Iptacopan, NM8074, Ravulizumab, ULTOMIRIS, SOLIRIS, and others.
Delve Insight’s comprehensive report on Atypical Hemolytic Uremic Syndrome Market Insights, Epidemiology and Market Forecast – 2034”
Find the full report here.
Read the full post.
Stay updated with Hemostasis Today.
-
Aug 23, 2026, 17:51Gurpreet Kaurr: A Proud Milestone in Haematology and Oncology
-
Aug 23, 2026, 17:33Kathrine Kaspersen: How Voluntary Plasma Donors Helped Transform Denmark’s Plasma Supply
-
Aug 23, 2026, 16:51Sthanu Subramanian: Empagliflozin and a Rise in Hematocrit
-
Aug 23, 2026, 16:50Lale Tokgözoğlu: New PCSK9i Research Published in the European Heart Journal
-
Aug 23, 2026, 16:44Eric Gehrie: Your 2026 Guide to the Essentials of Transfusion Medicine
-
Aug 23, 2026, 16:35Thomas Dayspring: The Overlooked Pathway in Cholesterol Homeostasis
-
Aug 23, 2026, 16:28Evan Mapelu: The People Who Make Cancer Care Meaningful
-
Aug 23, 2026, 16:09Felice Gragnano: New Publication on Aspirin Discontinuation After PCI for Acute Coronary Syndromes
-
Aug 23, 2026, 16:06Mostafa Faisal: Donor Type and Long-Term Quality of Life After HCT for Severe Aplastic Anemia